A rterial calcification, the presence of calcium deposits in the vessel wall, is a feature of advanced atherosclerosis and reduces elasticity and compliance of the vessel wall. 1 In clinics, it has been observed that arterial calcification, especially atherosclerotic calcification, is linked with plaque instability and predicts cardiovascular outcomes of patients. 2, 3 Accumulating evidence supports the concept that atherosclerotic calcification is not simply a passive precipitation of crystals, but an active cell-driven process characterized by osteogenic differentiation of vascular cells. [4] [5] [6] Studies reveal that osteoblastic differentiation of vascular smooth muscle cells (VSMC) plays an essential role in the development of atherosclerotic calcification. 4, 6 Numerous pathogenic factors, such as oxidative stress, 7, 8 high glucose, 9 and inflammation, 10 are involved in atherosclerotic calcification. However, the underlying mechanisms that drive the process are poorly characterized. AMP-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase that consists of 1 catalytic subunit (α) and 2 regulatory subunits (β and γ).
11, 12 The α subunit that controls catalytic activity has 2 isoforms, α1 and α2, which are differentially expressed in different tissues. 13 For example, the α1 isoform predominates in VSMCs, 14 macrophages, 15 and adipose tissues, 16 whereas cardiomyocytes express much higher amounts of AMPKα2. 17 Besides the wellknown role in metabolic regulation, recent evidence indicates novel roles for AMPK in the pathogenesis of cardiovascular diseases. 18 We and other groups reported that AMPK prevents atherosclerosis. 19, 20 However, knowledge of the role of AMPK in atherosclerotic calcification is limited.
Several recent studies reported that AMPK activation is negatively associated with chondrogenic and bone development 21, 22 and osteoblastic differentiation of VSMC in vitro. 23 Other studies found that AMPK promotes osteogenesis. 24 Hence, the role of AMPK in calcification and osteogenesis is highly controversial, and the contributions of AMPKα subunits to the development of atherosclerotic calcification in vivo remain unknown.
Runt-related transcription factor 2 (Runx2) is a key transcription factor that regulates osteoblastic differentiation, which leads to expression of bone matrix protein genes. 25 Its expression has been identified in atherosclerotic calcified human vascular tissue specimens and in calcifying aortic smooth muscle cells in mice. 26, 27 Recent studies further revealed that Runx2 in VSMC is crucial in the development of atherosclerotic calcification in mice. 5 It has been reported that AMPK activation negatively regulates Runx2 expression in VSMC in vitro, 28 but the mechanism is not clear. Here, we report that AMPK in VSMC plays a key role in regulating the initiation and progression of atherosclerotic calcification in vivo via Runx2 small ubiquitin-related modifier (SUMO)ylation and degradation pathway in vivo. /lyzM Cre mice. Atherosclerotic calcification in mice was generated as previously described. 5 Briefly, 8-week-old male mice in ApoE −/− background were fed with Western diet for 24 weeks. Calcification in atherosclerotic lesions of aortic roots and brachiocephalic arteries was determined by alizarin red and von Kossa staining. Immunofluorescence staining and Western blot were applied to determine the expression of Runx2.
Methods

ApoE
Quantitative values are expressed as the mean±SD and represent data from at least 3 independent experiments. After confirming that all variables were normally distributed by the Kolmogorov-Smirnov test followed by Q-Q plots analysis, statistical differences were determined by Student's t test for comparison between 2 groups and ANOVA followed by Bonferroni multiple comparison test for comparison among ≥3 groups. P values of <0.05 were considered statistically significant. All statistical calculations were performed using SPSS version 17.0 (SPSS Inc, Chicago, IL). Details of materials and experimental procedures are in the Methods in the Online Data Supplement. Table I ). As shown in Figure 1A and Online Figure I (Figure 1A and 1B; Online Figure I ). Moreover, ApoE −/− /AMPKα1 −/− but not ApoE −/− / AMPKα2 −/− exhibited significantly increased calcium content in aortas in comparison with ApoE −/− mice ( Figure 1C ). These results suggest that deletion of AMPKα1 promotes atherosclerotic calcification in vivo.
Results
Deletion of
AMPKα1 Deficiency Induces Aortic Runx2 Expression In Vivo
It has been reported that Runx2 in VSMCs is crucial for atherosclerotic calcification. 5 Therefore, we measured this important marker in our Western diet-induced atherosclerotic calcification model. As expected, in parallel with increased atherosclerotic calcification, ApoE −/− /AMPKα1 −/− mice showed markedly elevated expression of Runx2 in aortas compared with ApoE −/− mice, as indicated by both immunofluorescence staining (Figure 2A and 2B) and Western blot ( Figure 2C ). In contrast, there was no difference in aortic Runx2 expression between ApoE −/− and ApoE −/− /AMPKα2 −/− mice after Western diet treatment (Figures 2A through 3C) . Moreover, costaining of Runx2 with VSMC marker α-smooth muscle actin and macrophage marker CD68 indicated that Runx2 was mostly expressed in VSMC in ApoE
−/− mice ( Figure 2D ). These results suggest that AMPKα1 deficiency increases aortic Runx2 expression in vivo.
Administration of Metformin Suppresses DietInduced Atherosclerotic Calcification via AMPKα1 In Vivo
Our data imply that AMPKα1 but not AMPKα2 deletion increases atherosclerotic calcification. Therefore, we further tested whether activation of AMPKα1 may reduce atherosclerotic calcification in vivo. Chronic administration of metformin significantly reduced body weight and triglyceride levels in both ApoE −/− and ApoE −/− /AMPKα1 −/− mice, but did not alter other metabolic parameters (Online Table II ). More importantly, metformin treatment markedly inhibited calcium nodule formation in atherosclerotic plaque areas of aortic roots and brachiocephalic arteries and aortic calcium content in ApoE 
AMPKα1 Depletion in VSMC but Not in Macrophages Is Essential for Induction of DietInduced Atherosclerotic Calcification In Vivo
AMPKα1 is the predominant isoform in VSMC and macrophages. 14 We hypothesized that AMPKα1 in VSMC or Figure 4A , 4C, and 4E). There was no difference of body weight, blood glucose, total plasma cholesterol, and plasma triglycerides between groups (Online Table III ).
Taken together, these results indicate that loss of AMPKα1 in VSMC, but not in macrophages, promotes atherosclerotic calcification in vivo.
AMPKα1 Depletion Promotes Runx2 Expression and Induces Osteoblastic Differentiation of VSMC In Vitro
To further confirm the in vivo results, we isolated VSMC from wild-type (WT), AMPKα1 −/− , and AMPKα2 −/− mice, and cultured them in osteogenic media for 2 weeks. As depicted in Figure 5A , murine AMPKα1 −/− VSMC had significantly increased calcium nodule formation as demonstrated by alizarin red staining compared with WT VSMC. There was no difference of alizarin red staining between AMPKα2 −/− and WT VSMC. We further detected Runx2 expression in WT, AMPKα1-, and AMPKα2-deficient VSMC. As shown in Figure 5B , murine AMPKα1 −/− but not AMPKα2 −/− VSMC had significantly increased Runx2 expression compared with WT VSMC. This was further confirmed in human aortic VSMC, that AMPKα1-silenced human aortic VSMC had markedly 
AMPKα1 Activation Suppresses Oxidized LowDensity Lipoprotein-Induced Runx2 Expression in VSMC
Elevated oxidized low-density lipoprotein (ox-LDL) could induce Runx2 in VSMC and is associated with atherosclerotic calcification. 29, 30 We checked the effect of AMPK activation on Runx2 in human aortic VSMC. As expected, metformin supplementation significantly reduced ox-LDL-induced Runx2 upregulation ( Figure 5C ). However, although ox-LDL still triggered Runx2 upregulation, metformin did not reverse the effect in AMPKα1-silenced cells ( Figure 5C ).
AMPKα1 Deficiency-Induced Osteoblastic Differentiation of VSMC Is Runx2 Mediated
Runx2 in VSMC is essential for atherosclerotic calcification. 5 We hypothesized that Runx2 may be involved in AMPKα1 depletion-induced osteoblastic differentiation of VSMC. To confirm the role of Runx2 in AMPKα1 deficiency-induced VSMC osteoblastic differentiation, we used lentivirus of Runx2 shRNA to knock down Runx2 in VSMC. As expected, knock down of Runx2 by Runx2 shRNA lentivirus significantly suppressed osteoblastic differentiation induced by AMPKα1 depletion in AMPKα1 −/− VSMC as indicated by alizarin red staining ( Figure 5D ). These data suggest that AMPKα1 deficiency leads to Runx2 induction that is essential for AMPKα1 deficiency-induced osteoblastic differentiation in VSMC.
AMPKα1 Deficiency Suppresses Runx2 Degradation in VSMC
We next sought to determine how AMPKα1 depletion upregulates Runx2 in VSMC. AMPKα1 depletion increased Runx2 protein levels ( Figure 5B ). In contrast, the real-time polymerase chain reaction results indicated that AMPKα1 silencing in human aortic VSMC did not alter Runx2 mRNA levels when compared with scramble siRNA-transfected control The proteasome system is important for intracellular protein degradation, and it has been reported that Runx2 can be degraded by the proteasome. 31 To examine whether AMPKα1 depletion leads to Runx2 upregulation via proteasome degradation, AMPKα1 siRNA-treated human aortic VSMC were coincubated with MG132, a potent 26S proteasome inhibitor. MG132 treatment dramatically increased Runx2 expression in scramble siRNA-transfected cells as early as 4 hours, but had only mild effect in AMPKα1-silenced cells ( Figure 6B ). These results indicate that the activation of AMPKα1 is involved in promoting Runx2 degradation and AMPKα1 deficiency stabilizes Runx2 and prevents its degradation.
Activation of AMPK Leads to Runx2 Instability in VSMC
Because our data demonstrated that AMPKα1 deficiency suppresses Runx2 degradation, we hypothesized that activation of AMPK could lead to Runx2 instability. Indeed, metformin treatment significantly reduced Runx2 half-life ( Figure 6C ). 
Runx2 SUMOylation Leads to Its Instability and Proteasome Degradation in VSMC
It has been reported that Runx2 can be SUMOylated, 32 and SUMOylation of certain proteins could affect their stability. 33 We checked whether SUMOylation of Runx2 may affect its stability and degradation. We silenced protein inhibitor of activated STAT-1 (PIAS1), the SUMO E3-ligase of Runx2, 32 and ubiquitin conjugating enzyme 9 (UBC9), the unique E2 SUMOylation ligase, 34 to suppress Runx2 SUMOylation. As shown in Online Figure VA , silencing of PIAS1 and UBC9 significantly increased Runx2 expression in human aortic VSMC. Moreover, MG132 supplementation significantly increased Runx2 expression in scramble siRNA-transfected cells but had mild effect on PIAS1-or UBC9-silenced cells (Online Figure VB and VC) .
We next assayed the effect of Runx2 SUMOylation on its stability. As shown in Online Figure 2D , overexpression of PIAS1 and SUMO1 by electroporation to induce Runx2 SUMOylation in human aortic VSMC led to reduced half-life of WT-Runx2 compared with the control. However, PIAS1 and SUMO1 overexpression did not alter the half-life of K181R-Runx2 mutant, which abolishes Runx2 SUMOylation 32 (Online Figure VD) . These results suggest that SUMOylation of Runx2 reduces its stability and leads to proteasome degradation.
AMPK Activation Promotes Runx2 SUMOylation in VSMC
Because both AMPKα1 and SUMOylation lead to Runx2 instability, we further hypothesized that AMPKα1 may promote Runx2 SUMOylation and facilitate its degradation. As shown in Figure 7A , metformin treatment significantly induced Runx2 SUMOylation in human aortic VSMC, which could be abolished by compound C, the AMPKα inhibitor.
AMPKα1 Binds With Runx2 SUMO E3-Ligase PIAS1 in VSMC
We explored how AMPKα1 regulates Runx2 SUMOylation. We checked whether there is a link between AMPKα1 and PIAS1, the Runx2 SUMO E3-ligase. As indicated in Figure 7B , binding of AMPKα1/PIAS1 was evident in cell lysate pulled down by either PIAS1 or AMPKα immunoprecipitation.
AMPK Increases Phosphorylation of PIAS1 at Serine 510 in VSMC
Based on our findings that AMPKα1 binds with PIAS1, we proposed a mechanism by which AMPK might directly regulate PIAS1 function. Post-translational modifications of PIAS1, including serine phosphorylation, are known to regulate its SUMO E3-ligase activity. 35 We reasoned that AMPK might directly phosphorylate PIAS1 serine(s). To test this hypothesis, we first measured total serine phosphorylation of PIAS1 in VSMCs after metformin treatment. As shown in Figure 7C , exposure of human aortic VSMC to metformin increased the serine phosphorylation of PIAS1. Conversely, inhibition of AMPK by compound C dramatically suppressed the effect ( Figure 7C ). Neither metformin nor compound C altered the PIAS1 total protein levels ( Figure 7C ).
Next, we determined the serine residue(s) of PIAS1 to be phosphorylated by AMPKα1. GPS 3.0 was applied first to predict the potential phosphorylation site of PIAS1 by AMPK. 36 To confirm these predicted phosphorylation sites, we generated 3 site-directed mutant constructs of PIAS1 (serine (S) to alanine (A) at S90A, S510A, and S626A). In human aortic VSMC transfected with WT-PIAS1, treatment with metformin significantly increased its serine phosphorylation. This increase was abolished in cells transfected with PIAS1 S510A (Figure 7D ).
PIAS1 Serine 510 Phosphorylation Is Required for AMPK Activation-Induced Runx2 SUMOylation
Reports indicate that PIAS1 serine phosphorylation promotes its SUMO E3-ligase activity. 35 We next assayed whether PIAS1 S510 phosphorylation plays a role in AMPK activation-triggered Runx2 SUMOylation. As shown in Figure 8A , metformin treatment to increase AMPKα phosphorylation induced Runx2 SUMOylation in WT-PIAS1-transfected human aortic VSMC. However, overexpression of S510A-mutated PIAS1 in human aortic VSMC, which suppresses the endogenous phosphorylation of PIAS1 at serine 510, markedly abolished metformin-caused Runx2 SUMOylation ( Figure 8A ). This result suggests that PIAS1 serine 510 phosphorylation is required for AMPK activation-induced Runx2 SUMOylation.
Mutation of PIAS1 Serine 510 to Glutamic Acid Abolishes AMPKα1 Depletion-Induced Runx2 Upregulation in VSMC
Because AMPKα1 directly phosphorylates PIAS1 at serine 510, which promotes Runx2 SUMOylation, we next tested whether serine 510 phosphorylation of PIAS1 regulates Runx2 expression in VSMC. As indicated in Figure 8B , AMPKα1 silencing increased Runx2 expression in both vector and WT-PIAS1-transfected human aortic VSMC. However, in AMPKα1-silenced human aortic VSMC, simultaneous overexpression of PIAS1 S510E mutant, which mimicked the endogenous phosphorylation of PIAS1 at serine 510, significantly inhibited AMPKα1 silencing-induced Runx2 upregulation compared with WT-PIAS1-transfected cells ( Figure 8B ).
Mutation of PIAS1 Serine 510 to Alanine Suppresses Reduction Effect of Metformin on ox-LDL-Induced Runx2 Expression in VSMC
Our data indicate that metformin reduces ox-LDL-induced Runx2 via activation of AMPKα1, and AMPKα1 phosphorylates PIAS1 to promote Runx2 SUMOylation and degradation. Therefore, we reasoned that blockage of PIAS1 serine 510 phosphorylation may abolished the effect of metformin on reducing ox-LDL-induced Runx2 expression. In the absence of ox-LDL, metformin had only marginal effects on the levels of Runx2 ( Figure 8C ). In contrast, ox-LDL alone markedly increased the levels of Runx2 in cells overexpressed control vector, WT-PIAS1, or S510A-PIAS1 ( Figure 8C ). As depicted in Figure 8C , metformin reduced ox-LDL-induced Runx2 expression in both WT-PIAS1-and S510A-PIAS1-overexpressed human aortic VSMC. Overexpression of PIAS1 S510A mutant, which did not alter the endogenous PIAS1 serine 510 phosphorylation, markedly alleviated metformin's effect on reducing ox-LDL-induced Runx2 expression ( Figure 8C ). These data suggest that PIAS1 phosphorylation at serine 510 is required for AMPK activation to inhibit ox-LDL-induced Runx2 expression. 
PIAS1 Ablation Abolishes the Inhibitory Effect of Metformin on ox-LDL-induced Osteoblastic Differentiation of VSMC
We further tested whether PIAS1 plays a role in osteoblastic differentiation in VSMC, and whether it could affect metformin's effect on ox-LDL-induced osteoblastic differentiation. As shown in Online Figure III , ox-LDL significantly promoted calcium nodule formation in human aortic VSMC. This was ablated by coadministration of metformin. Meanwhile, PIAS silencing achieved by lentivirus PIAS1 shRNA transfection markedly induced calcium nodule formation, and ox-LDL further enhanced this effect (Online Figure VI) . However, metformin could not inhibit calcium nodule formation in the presence of PIAS1 silencing either in the presence or in the absence of ox-LDL (Online Figure VI) .
Discussion
The present study has, for the first time, demonstrated that AMPKα1 activation in VSMC prevents the development of atherosclerotic calcification. Deletion of AMPKα1 but not of AMPKα2 promotes atherosclerotic calcification, and more importantly, the AMPKα1 in VSMC contributes to the effect. Metformin treatment, which activates AMPKα1, significantly inhibited atherosclerotic calcification in vivo. Mechanistically, we found that AMPKα1 binds and phosphorylates PIAS1, the SUMO E3-ligase of Runx2, at serine 510, to promote Runx2 instability via proteasome-mediated degradation.
The first important finding is that AMPKα1 deficiency in VSMC promotes atherosclerotic calcification in vivo. This conclusion is supported by several observations. First, our cellular data showed that AMPKα1 deficiency, rather than AMPKα2 deficiency, stimulates osteoblastic differentiation of VSMC. Next, global deficiency of AMPKα1 but not of AMPKα2 in ApoE −/− mice promotes Western dietinduced atherosclerotic calcification. Furthermore, Runx2 was expressed in VSMC but not in macrophages in plaque areas. It should be noted that we applied CD68 as the macrophage marker. Recent studies indicate that CD68 is not only expressed in macrophages but also in several other cell types. 37 This circumstance might be a limitation of our study. Finally, deficiency of AMPKα1 in VSMC enhances atherosclerotic calcification. These data indicate that AMPKα1 in VSMC plays a protective role in preventing atherosclerotic calcification.
We found that Runx2 plays an important role in AMPKα1 deficiency-caused atherosclerotic calcification. The expression of Runx2 is low in normal arteries, and it has been demonstrated that Runx2 in VSMC is essential for osteoblastic differentiation of VSMC in vitro 8 and atherosclerotic calcification in vivo. 5 Runx2 has been shown to induce ALP activity and the expression of bone matrix protein genes, including osteocalcin, bone sialoprotein, and osteopontin, 38 to promote osteoblastic differentiation of VSMC. 7 Studies also indicate that Runx2 induction in VSMC activates RANKL, which mediates the cross talk between calcifying VSMC and migration and differentiation of macrophages into osteoclast-like cells in the atherosclerotic lesions. 5 Our data show that AMPKα1 depletion dramatically increased VSMC Runx2 expression both in vitro and in vivo. The essential role of Runx2 is further supported by the results that shRNA silencing of Runx2 dramatically prevents osteoblastic differentiation in AMPKα1-depleted VSMC.
One interesting finding is that AMPKα1 activation leads to Runx2 instability in VSMC. Our data demonstrate that AMPKα1 deficiency increased Runx2 protein levels without corresponding increase in Runx2 mRNA levels. This suggests that post-translational regulation of Runx2 is responsible for the process. Indeed, we found that AMPK activation by metformin reduced the half-life of Runx2. The ability of MG132, a proteasome inhibitor, that significantly increased Runx2 in control but not in AMPKα1-silenced cells further indicates that AMPKα1 leads to Runx2 instability and degradation by proteasome.
One plausible hypothesis of AMPKα1-mediated Runx2 instability is that AMPKα1 regulates the post-translational modifications of Runx2 that facilitates its degradation. Because AMPK is a well-known serine/threonine(s) protein kinase, and Runx2 phosphorylation has been shown to be linked with increased instability, 39 it is reasonable to hypothesize that AMPKα1 may phosphorylate Runx2 to confer instability. However, we did not detect binding of Runx2 and AMPKα1 (data not shown). Another hypothesis would be that AMPKα1 promotes Runx2 ubiquitination and degradation. Indeed, it has been reported that several E3 ubiquitin ligases promote Runx2 ubiquitination and degradation in osteoblasts, such as Smurf1, Smurf2, and WWP1. [40] [41] [42] We also checked whether AMPKα1 may regulate Runx2 via these E3 ubiquitin ligase. However, we did not find evidence of AMPKα1 regulating these E3 ubiquitin ligases or these E3 ubiquitin ligases regulating Runx2 in VSMC (data not shown).
It has been reported that Runx2 can be SUMOylated, 32 and certain protein SUMOylation, is associated with degradation. 34 Our results demonstrate that AMPK activation causes Runx2 SUMOylation. Our findings further expand the understanding of Runx2 SUMOylation, indicating that SUMOylation of Runx2 at K181 results in its instability. However, the mechanism by which SUMOylation enhances Runx2 degradation is unclear, but may attribute to the conformational change of the protein, which may facilitate its ubiquitination and attachment to proteasome. 34 Another important finding is that AMPKα1 binds and phosphorylates PIAS1, the SUMO E3-ligase of Runx2, 32 at serine 510, to promote Runx2 SUMOylation. Phosphorylation of PIAS1 is reported to promote its SUMO E3-ligase activity. 35 We speculated that AMPKα1 may directly phosphorylate PIAS1 and therefore regulate Runx2 SUMOylation SUMOylation is supported by the data that PIAS1 serine 510 mutation to alanine blocks AMPK activation-induced Runx2 SUMOylation in VSMC.
As all our data indicate the preventive role of AMPKα1 activation in osteoblastic differentiation of VSMC and atherosclerotic calcification, one important question is raised: Could AMPK activation be used as a strategy to inhibit atherosclerotic calcification? Indeed, we found that metformin could activate AMPKα1 to suppress ox-LDL-induced Runx2 upregulation in VSMC, and further prevent ox-LDL-induced osteoblastic differentiation of VSMC via PIAS1 signaling. And more importantly, chronic administration of metformin prevented diet-induced atherosclerotic calcification that is AMPKα1-dependent in vivo. These data not only imply the protective effect of metformin on atherosclerotic calcification but also further support the preventive role of AMPKα1 in atherosclerotic calcification.
Several clinical trials indicate that metformin effectively prevents cardiovascular outcomes of diabetic patients with coronary atherosclerotic heart diseases. 43 According to our study, the beneficial effect of metformin may, at least partially, be associated with reducing atherosclerotic calcification, which subsequently stabilize the plaques. Our study may provide a rationale to pursue AMPKα1 activation as a strategy to prevent atherosclerotic calcification in patients having coronary atherosclerotic heart diseases.
We applied metformin as the strategy to activate AMPK in vivo and in vitro. However, metformin exerts other potentially relevant effects. It has been reported to reduce endoplasmic reticulum stress. 44 Endoplasmic reticulum stress has been shown to be involved in vascular calcification. 45 Also, metformin activates both AMPKα1 and AMPKα2. It might be possible that medications that are selective for AMPKα1 and more potent would have more efficacy in preventing atherosclerotic calcification in vivo.
One report suggests that metformin inhibited calcification in VSMC via the AMPK-eNOS-NO pathway. 28 However, eNOS is majorly expressed in endothelial cell but not in VSMC. 46 Compared with other NOS isoforms, eNOS only produces limited NO. 46 Therefore, although AMPK activation could upregulate eNOS expression in VSMC, the subtle eNOS expression in VSMC could not upregulate much NO production in VSMC and limit this signaling in regulating VSMC osteoblastic differentiation. This suggests that AMPK-eNOS-NO pathway might not been the major signaling involving AMPK-Runx2 regulation.
Studies indicate that Runx2 in VSMC promotes vessel stiffness. 47 Because our study demonstrates that AMPKα1 prevents Runx2 expression in VSMC, it would be possible that AMPKα1 activation may improve vascular compliance, which is closely associated with cardiovascular events, especially in aged populations. 48 We are conducting the study of AMPK and age-related arterial stiffness and will publish the data in the future.
It is interesting to note that the roles of AMPK have opposite roles in osteoblasts and VSMC differentiation. Most studies indicate that AMPK promotes osteogenesis of bone, 22 ,49 yet AMPK activation attenuates osteoblastic calcification in VSMC. Exact reasons for these differences are unknown, which might be because of the differences of various enzymes and molecules in different cell types. Recent study reports that AMPK phosphorylates Smurf1, the ubiquitin E3-ligase of Runx2, in osteoblast. 50 This phosphorylation blunts Smurf1's ubiquitin E3-ligase activity and thus promotes Runx2 expression in osteoblast. 50 However, we found silencing of Smurf1 could not alter Runx2 expression in VSMC (data not shown). This might explain why the roles of AMPK in osteoblastic differentiation are opposite in VSMC and osteoblast. Further investigation is warranted.
In summary, the present studies have demonstrated a novel link between AMPKα1 in VSMC and atherosclerotic calcification and uncovered a novel mechanism underlying the regulation of PIAS1 phosphorylation by AMPKα1. The latter induces Runx2 SUMOylation and instability to prevent VSMC osteoblastic differentiation. These findings have identified AMPKα1 activation as a potential target for preventing atherosclerotic calcification in patients with coronary atherosclerotic heart diseases.
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What Is Known?
• Atherosclerotic calcification in closely linked with plaque instability.
Patients with atherosclerotic calcification in coronary arteries have a higher risk of cardiovascular events.
• The serine/threonine protein kinase AMPK participates in the pathogenesis of various cardiovascular diseases.
• It has been reported that metformin and adiponectin inhibit hyper phosphate-induced VSMC osteoblastic differentiation in vitro.
• The transcription factor Runx2 in VSMC is essential for the development of atherosclerotic calcification in vivo.
What New Information Does This Article Contribute?
• AMPKα1 deficiency in VSMC contributes to diet-induced atherosclerotic calcification in mice.
• Administration of metformin prevents diet-induced atherosclerotic calcification via AMPKα1 in vivo.
• AMPKα1 deficiency promotes osteoblastic differentiation of VSMC via increasing Runx2 protein expression.
• AMPKα1 phosphorylates PIAS1, the SUMO E3-ligase of Runx2, at serine 510, to enhance Runx2 SUMOylation and subsequently leads to its instability and proteasome degradation.
Atherosclerotic calcification is an independent risk factor for cardiovascular events. Our study demonstrates a novel link between AMPKα1 in VSMC and atherosclerotic calcification, and reveals that AMPKα1 activation enhances PIAS1 phosphorylation at serine 510, to promote Runx2 SUMOylation resulting in subsequent instability. Deletion of AMPKα1 in VSMC accelerates diet-induced atherosclerotic calcification in vivo. Metformin treatment markedly prevents diet-induced atherosclerotic calcification via AMPKα1 in vivo. Thus, these findings have identified AMPKα1 activation as a potential target for preventing atherosclerotic calcification in patients with coronary atherosclerotic heart diseases. 
Animals
ApoE -/-(C57BL/6 background) and SM22 Cre (C57BL/6 background) mice were purchased from Jackson Laboratories (Bar Harbor, ME). AMPKα1 -/-and AMPKα2 -/-mice were generated as previously described 1 , and backcrossed into C57BL/6 background for at least ten generations. AMPKα1 floxed (AMPKα1 f/f ) mice were kindly provided by Dr. Benoit Viollet. ApoE -/-/AMPKα1 -/-and ApoE -/-/AMPKα2 -/-mice were generated by crossing AMPKα1 -/-or AMPKα2 -/-mice with ApoE -/-mice. AMPKα1
VSMC-or macrophage-specific deficient mice in ApoE -/-background, were generated by 
Cell culture
Primary murine VSMC were isolated from mouse aorta and cultured in growth media as described previously 2 . Human aortic VSMC were purchased from Life Technology (Grand Island, NY) and cultured in M231 medium (Life Technology) supplemented with growth factors (Life Technology). All experiments were performed with VSMC at passages 3 to 5.
Animal experiments
Male ApoE -/-background mice were fed with western diet for 24 weeks to generate atherosclerotic calcification in vivo 3 
Immunofluorescence staining of aortic roots and brachiocephalic arteries
For the immunofluorescence staining analysis, slides were stained with antibodies specific to Runx2, α-SMA, and CD68. Olympus fluorescence microscope was used for images collecting. Image-Pro Plus 6.0 (Media Cybernetics, Rockville, MD) was applied for data quantification.
Determination of aortic calcium content
Calcium content in descending aortas was measured using the calcium detection kit (Abcam) as described previously 3 . The amount of vascular calcium was normalized by the dry weight of the tissues and expressed as millimolar/gram dry weight.
Preparation of oxLDL
OxLDL was achieved by copper oxidation of human LDL 4 . Briefly, LDL was incubated with 10mmol/l CuSO 4 for 18h at 37°C and terminated by adding 1mmol/l EDTA. OxLDL was then dialyzed, sterilized by filtering, and diluted to 1mg/ml in PBS.
The prepared oxLDL was stored at 4°C and used within 2 weeks.
Plasmids
The Myc-PIAS1, GFP-Runx2, HA-SUMO1 and control pCMV6-entry plasmid were purchased from Origene (Rockville, MD). PIAS1 S90A, S510A, S626A, and S510E mutants (Myc tagged) was generated using the QuickChange II site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. The mutation was verified by DNA sequencing.
Cellular small-interfering RNA and plasmids transfection
Human aortic VSMC were transfected with control small-interfering RNA were selected by treatment with 5μg/ml puromycin (Santa Cruz Biotechnology) for 7 days.
In vitro VSMC calcification
In vitro VSMC calcification was induced in osteogenic media containing 0.25mmol/L L-ascorbic acid and 10mmol/L β-glycerophosphate for 2 weeks as described previously 3 . Calcification was determined by alizarin red staining and quantified as described previously 5 .
Immunoprecipitation and western blot analysis
For immunoprecipitation, samples were collected and lysed in 20mM Tris-HCl pH 7.5 lysis buffer. Supernatants were immunoprecipitated with 5 µg of anti-myc, anti-AMPK, or anti-PIAS1 overnight accordingly and then incubated with protein A sepharose CL-4B (VWR, Suwanee, GA) for another 3 h at 4 °C. Cell lysates or tissue homogenates were subjected to western blot analysis, as described previously 2 . For detection of SUMOylation, 50mmol/L NEM was added to the lysis buffer to protein extraction. Importantly, the samples cannot be boiled for SUMOylation determination.
The intensity (area × density) of the individual bands on Bands were quantified by densitometry using Quantity One Software (Bio-Rad, Hercules, CA).
RNA extraction and quantitative PCR (qPCR)
Cell total RNA was extracted using the TRI Reagent® Solution (AM9738; Life technologies) and 1µg of RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis Kits (Bio-Rad). PCR amplification was performed using the SYBR PCR mix (Bio-Rad) with primers of Runx2: 5'-CTTCACAAATCCTCCCCAAG-3'; 5'-GAATGCGCCCTAAATCACTG-3', and GAPDH: 5'-GGAGTCAACGGATTTGGT-3';
5'-GTGATGGGATTTCCATTGAT-3', which was served as internal calibrator.
Statistical analysis
Quantitative values are expressed as the mean ± SD and represent data from at least three independent experiments. After confirming that all variables were normally distributed by the Kolmogorov-Smirnov test followed by Q-Q plots analysis, statistical differences were determined by Student's t-test for comparison between two groups and ANOVA followed by Bonferroni's multiple comparison test for comparison among three or more groups. P values of less than 0.05 were considered statistically significant. All statistical calculations were carried out using SPSS version 17.0 (SPSS Inc, Chicago, IL, USA).
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